Search the Newsreel

Ionis (IONS) Stock Looks Like A Bargain On Value But Full On Sales

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ionis Pharmaceuticals stock carries a strong three year return record alongside a high overall value score, yet current market multiples still point to the shares …

Empowered Funds LLC Buys 16,525 Shares of Alpha Metallurgical Resources, Inc. $AMR

Empowered Funds LLC increased its stake in Alpha Metallurgical Resources, Inc. (NYSE:AMR) by 79.4% in the first quarter, adding 16,525 shares and bringing its total holdings to 37,347 shares valued at approximately $7.7 million. Other institutional investors also adjusted their positions in AMR, which …

Bank Hapoalim BM Invests $2.67 Million in Zscaler, Inc. $ZS

Bank Hapoalim BM recently acquired 18,885 shares of Zscaler, Inc. (NASDAQ:ZS) worth approximately $2.67 million during the second quarter. This investment is part of broader institutional interest, with several other large investors also increasing their stakes in the cloud security company. Despite recent analyst …

Inspire Medical Systems (INSP) Stock May Be Cheap After A 74% Fall

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Inspire Medical Systems stock has had a difficult run over the past three years, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and market multiples …

Phathom Pharmaceuticals (PHAT) Stock Sees Modest Fair Value Cut After Analyst Target Cuts

Phathom Pharmaceuticals (PHAT) has experienced a modest fair value cut from US$23.70 to US$21.50 following analyst target revisions. This adjustment is due to updated Q2 results, revised 2026 revenue guidance, and new perspectives on their drug Voquezna's commercial path. While some firms remain bullish …

Zscaler, Inc. (NASDAQ:ZS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Zscaler, Inc. (NASDAQ:ZS) has received a consensus "Moderate Buy" rating from analysts, with 34 out of 41 firms recommending to buy the stock. The average 12-month price target is set at $214.21, following recent quarterly results that surpassed expectations, reporting adjusted EPS of $1.08 …

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of "Moderate Buy" by Brokerages

Tarsus Pharmaceuticals (NASDAQ:TARS) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $90.50, significantly higher than its current share price of $69.20. The company recently reported quarterly revenue of $173.91 million, surpassing estimates, but its loss per …

Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination

Citius Pharmaceuticals reported promising early results for its approved drug LYMPHIR in new indications, including an 86% objective response rate in a Phase 1 CAR-T combination trial for diffuse large B-cell lymphoma and a 24% ORR in gynecologic malignancies. The company also announced strong …

Will Mirum Pharmaceuticals' (MIRM) Widening Net Losses Test Its Growth-Focused Investment Narrative?

Mirum Pharmaceuticals reported a significant net loss for Q2 and H1 2026, with basic loss per share rising, which highlights increased costs relative to revenue. This widening loss intensifies focus on cash burn and funding risks, despite upcoming clinical and regulatory catalysts such as …

Wall Street Zen Downgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to Sell

Wall Street Zen has downgraded Mirum Pharmaceuticals (NASDAQ:MIRM) from "hold" to "sell," despite the company reporting better-than-expected quarterly revenue of $176.24 million, a 37.9% increase year-over-year. The downgrade comes as the company missed earnings per share estimates, reporting a loss of $1.06 against a …

Responsive Playbooks and the ETON Inflection

This article provides an AI-driven analysis for Eton Pharmaceuticals Inc. (NASDAQ: ETON), highlighting weak near and mid-term sentiment but a positive long-term outlook. It details specific trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report suggests …

Orthofix (OFIX) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief IR and Communications Officer - Julie Dewey President and Chief Executive Officer - Massimo Calafiore Chief Financial Officer - Julie Andrews Full Conference Call Transcript Operator: Thank …

Rigel Pharmaceuticals (RIGL) Stock Sees Fair Value Lift As Veppanu Launch Adds Growth Hope

Rigel Pharmaceuticals (RIGL) has seen its fair value estimate increase from US$51.6 to US$61.2 per share, primarily due to the launch of Veppanu in the U.S. and the international potential of Rezlidhia through a partnership with Kissei. Analysts, such as H.C. Wainwright, view Veppanu …

Why Eton Pharmaceuticals (ETON) Is Up 32.0% After Q2 Earnings Surge And Raised 2026 Outlook

Eton Pharmaceuticals (ETON) saw its stock rise 32.0% after reporting a significant Q2 2026 earnings turnaround, with revenue surging to US$37.59 million and net income reaching US$11.58 million. The company also raised its full-year 2026 revenue guidance to at least US$145 million and expanded …

Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – DUS:1RV

This article provides financial data for Rhythm Pharmaceuticals, Inc. (DUS:1RV) on the Dusseldorf Stock Exchange, specifically focusing on its enterprise value to revenue forward. It notes that the market is closed with no trades recorded at the time of publication. The content is presented …

California Water Service Group Named a Top Workplace in USA for Second Consecutive Year

California Water Service Group has been recognized as a Top Workplace in the USA for the second consecutive year by Energage. This award is based on employee feedback gathered through an anonymous survey, highlighting the company's commitment to fostering an exceptional workplace culture. The …

Orthofix Medical Sees Reimbursement Rebound, but Spine Slump Clouds Outlook

Orthofix Medical's updated outlook reflects a rebound in bone growth stimulation reimbursement and improved trends in biologics and limb reconstruction, partially offset by a steeper-than-expected decline among smaller U.S. spine distributors. The company expects third-quarter revenue to be similar to the second quarter with …

Outset Medical (OM) Q2 2026 Earnings Call Transcript

How NuScale’s Advanced Fuel Recycling Collaboration At NuScale Power (SMR) Has Changed Its Investment Story

In August 2026, Curio announced it had signed a Memorandum of Understanding with NuScale Power and Framatome to evaluate integrated nuclear fuel cycle solutions using Curio's NuCycle recycling technology, aiming to support both U.S. and international next-generation nuclear deployments. This collaboration highlights NuScale's potential …

Intuitive Surgical (ISRG): 3 Reasons We Love This Stock

Intuitive Surgical (ISRG): 3 Reasons We Love This Stock Over the last six months, Intuitive Surgical's shares have sunk to $400.75, producing a disappointing 17.5% loss - a stark contrast to the S&P 500's 13% gain. This might have investors contemplating their next move. …

Inspire Medical Systems (INSP) Updates Guidance As Valuation Questions Persist

US Physical Therapy Appoints New Executive Vice President CFO

Shanghai Fudan Zhangjiang Bio Pharmaceutical Ltd (SEHK:1349) Stock Profit Rebound Raises Durability Questions

Kestra Medical Technologies CEO Brian Webster sells $692,214 in stock

Kestra Medical Technologies CEO Brian Webster recently sold $692,214 worth of company stock across three transactions between July 30 and August 3, 2026. These sales were nondiscretionary, executed to cover tax withholding obligations related to restricted stock unit vesting. The company has seen significant …

Kestra Medical Technologies officer Traci Umberger sells $512,791 By Investing.com

Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket

Eton Pharmaceuticals (NASDAQ: ETON) saw its shares rise significantly in pre-market trading after reporting stronger-than-expected second-quarter financial results and providing an optimistic revenue guidance for FY26. The company exceeded analyst consensus estimates for both earnings per share and sales. The article also lists other …

Is BioMarin Pharmaceutical (BMRN) Still Cheap As 2026 Guidance Rises And Amicus Adds Growth?

BioMarin Pharmaceutical (BMRN) has updated its 2026 guidance and completed the Amicus acquisition, leading to increased attention on the stock. Despite strong short-term momentum and a "22% Undervalued" narrative, the article highlights the need for investors to consider inherent risks, such as reliance on …

ETFs Investing in Regeneron Pharmaceuticals, Inc. Stocks

This article provides a comprehensive list of Exchange Traded Funds (ETFs) that invest in Regeneron Pharmaceuticals, Inc. (RGO) stocks. The list, sorted by market value, details each fund's symbol, market value, weight of RGO stock, issuer, management style, focus, expense ratio, assets under management …

Is Teva Pharmaceutical Industries (TEVA) A Bargain On Its TEV 408 Phase 2b Move?

Kestra Medical Technologies CCO sells $642k in shares

Kestra Medical CBO Timothy Moran sells $348,310 in shares

Kestra Medical's CBO, Timothy P. Moran, sold $348,310 worth of common shares in late July and early August 2026 to cover tax withholding obligations. Following these transactions, Moran directly owns 66,345 shares. The stock has appreciated significantly since then, despite the company missing Wall …

Kestra Medical Technologies officer Traci Umberger sells $512,791

Traci S. Umberger, General Counsel and Chief Administrative Officer at Kestra Medical Technologies, sold common shares worth $512,791 between July 30 and August 3, 2026. These non-discretionary sales were conducted to cover tax withholding obligations related to restricted stock unit vesting. Following these transactions, …

ANI Pharmaceuticals (ANIP) Could Be 34% Undervalued As Earnings And Guidance Hold

ANI Pharmaceuticals (ANIP) is currently in focus after reporting its Q2 and H1 2026 results and reaffirming its full-year net revenue outlook of $1,080 million to $1,140 million. Despite recent strong earnings, the stock has seen a short-term decline, though it shows significant long-term …

Calumet (CLMT) Beat Second Quarter Estimates, Is The Stock Already Expensive?

Ionis Pharmaceuticals (IONS) Has A $92 Fair Value Narrative, Is The Stock A Bargain?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ionis Pharmaceuticals (IONS) has drawn investor attention after recent share price moves, with the stock up over the past month but down over the past …

Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks

Winners And Losers Of Q2: ANI Pharmaceuticals (NASDAQ:ANIP) Vs The Rest Of The Generic Pharmaceuticals Stocks Quarterly earnings results are a good time to check in on a company's progress, especially compared to its peers in the same sector. Today we are looking at …